194 related articles for article (PubMed ID: 29472252)
41. Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.
Peterson LM; Kipp BR; Halling KC; Kerr SE; Smith DI; Distad TJ; Clayton AC; Medeiros F
Int J Gynecol Pathol; 2012 May; 31(3):195-205. PubMed ID: 22498935
[TBL] [Abstract][Full Text] [Related]
42. A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.
Schofield L; Grieu F; Goldblatt J; Amanuel B; Iacopetta B
Fam Cancer; 2012 Mar; 11(1):1-6. PubMed ID: 22120844
[TBL] [Abstract][Full Text] [Related]
43. Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population.
West NP; Gallop N; Kaye D; Glover A; Young C; Hutchins GGA; Brockmoeller SF; Westwood AC; Rossington H; Quirke P;
Histopathology; 2021 Nov; 79(5):690-699. PubMed ID: 33872400
[TBL] [Abstract][Full Text] [Related]
44. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
[TBL] [Abstract][Full Text] [Related]
45. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
46. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have a high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories.
Bocciarelli C; Caumont C; Samaison L; Cariou M; Aline-Fardin A; Doucet L; Roudié J; Terris B; Merlio JP; Marcorelles P; Cappellen D; Uguen A
Hum Pathol; 2021 Aug; 114():99-109. PubMed ID: 34019865
[TBL] [Abstract][Full Text] [Related]
47. Recent discoveries in the molecular genetics of Lynch syndrome.
Boland CR
Fam Cancer; 2016 Jul; 15(3):395-403. PubMed ID: 27038793
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive Paired Tumor/Germline Testing for Lynch Syndrome: Bringing Resolution to the Diagnostic Process.
Salvador MU; Truelson MRF; Mason C; Souders B; LaDuca H; Dougall B; Black MH; Fulk K; Profato J; Gutierrez S; Jasperson K; Tippin-Davis B; Lu HM; Gray P; Shah S; Chao EC; Ghahramani N; Landsverk M; Gau CL; Chen D; Pronold M
J Clin Oncol; 2019 Mar; 37(8):647-657. PubMed ID: 30702970
[TBL] [Abstract][Full Text] [Related]
49. A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting.
Ramsoekh D; Wagner A; van Leerdam ME; Dinjens WN; Steyerberg EW; Halley DJ; Kuipers EJ; Dooijes D
Gut; 2008 Nov; 57(11):1539-44. PubMed ID: 18625694
[TBL] [Abstract][Full Text] [Related]
50. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening.
Bessa X; Ballesté B; Andreu M; Castells A; Bellosillo B; Balaguer F; Castellví-Bel S; Paya A; Jover R; Alenda C; Titó L; Martinez-Villacampa M; Vilella A; Xicola RM; Pons E; Llor X;
Clin Gastroenterol Hepatol; 2008 Feb; 6(2):206-14. PubMed ID: 18096441
[TBL] [Abstract][Full Text] [Related]
51. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years.
Leenen CH; van Lier MG; van Doorn HC; van Leerdam ME; Kooi SG; de Waard J; Hoedemaeker RF; van den Ouweland AM; Hulspas SM; Dubbink HJ; Kuipers EJ; Wagner A; Dinjens WN; Steyerberg EW
Gynecol Oncol; 2012 May; 125(2):414-20. PubMed ID: 22306203
[TBL] [Abstract][Full Text] [Related]
52. Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment.
Rigter LS; Snaebjornsson P; Rosenberg EH; Atmodimedjo PN; Aleman BM; Ten Hoeve J; Geurts-Giele WR; ; van Ravesteyn TW; Hoeksel J; Meijer GA; Te Riele H; van Leeuwen FE; Dinjens WN; van Leerdam ME
Gut; 2018 Mar; 67(3):447-455. PubMed ID: 29439113
[TBL] [Abstract][Full Text] [Related]
53. Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer.
Siraj AK; Prabhakaran S; Bavi P; Bu R; Beg S; Hazmi MA; Al-Rasheed M; Al-Assiri M; Sairafi R; Al-Dayel F; Al-Sanea N; Uddin S; Al-Kuraya KS
Cancer; 2015 Jun; 121(11):1762-71. PubMed ID: 25712738
[TBL] [Abstract][Full Text] [Related]
54. Success of referral to genetic counseling after positive lynch syndrome screening test.
Irons RF; Contino KM; Horte JJ; Levin B; Mattie KD; Wight M; Kwiatt ME; Behling KC; Edmonston TB; McClane SJ
Int J Colorectal Dis; 2017 Sep; 32(9):1345-1348. PubMed ID: 28664346
[TBL] [Abstract][Full Text] [Related]
55. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome.
Rahner N; Friedrichs N; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
J Pathol; 2008 Jan; 214(1):10-6. PubMed ID: 17973250
[TBL] [Abstract][Full Text] [Related]
56. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
[TBL] [Abstract][Full Text] [Related]
57. Genetic testing for hereditary nonpolyposis colorectal cancer.
Hoedema R; Monroe T; Bos C; Palmer S; Kim D; Marvin M; Luchtefeld M
Am Surg; 2003 May; 69(5):387-91; discussion 391-2. PubMed ID: 12769209
[TBL] [Abstract][Full Text] [Related]
58. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
59. Importance of PCR-based Tumor Testing in the Evaluation of Lynch Syndrome-associated Endometrial Cancer.
Bruegl AS; Kernberg A; Broaddus RR
Adv Anat Pathol; 2017 Nov; 24(6):372-378. PubMed ID: 28820751
[TBL] [Abstract][Full Text] [Related]
60. Heterogenous MSH6 loss is a result of microsatellite instability within MSH6 and occurs in sporadic and hereditary colorectal and endometrial carcinomas.
Graham RP; Kerr SE; Butz ML; Thibodeau SN; Halling KC; Smyrk TC; Dina MA; Waugh VM; Rumilla KM
Am J Surg Pathol; 2015 Oct; 39(10):1370-6. PubMed ID: 26099011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
